• صفحه اصلی
  • فراوانی ژن هایcas سیستمCRISPR/Cas در سویه‌های اشریشیا کلی تولید کننده ESBL، جداشده از عفونت‌های دستگاه ادراری  

اشتراک گذاری

آدرس مقاله


کد مقاله : JMW-2106-1987 (R1) بازدید : 203 صفحه: 6 - 17

10.30495/jmw.2022.1934160.1987

نوع مقاله: پژوهشی

فراوانی ژن هایcas سیستمCRISPR/Cas در سویه‌های اشریشیا کلی تولید کننده ESBL، جداشده از عفونت‌های دستگاه ادراری  

محورهای موضوعی : باکتری شناسی

ندا مریخی 1 , جمیله نوروزی 2 , علی ناظمی 3 , مهرداد هاشمی 4 , رباب رفیعی طباطبایی 5

1 - گروه میکروب شناسی، دانشکده علوم زیستی، دانشگاه آزاد اسلامی، واحد تهران شمال، تهران، ایران
2 - گروه میکروب شناسی، دانشکده علوم زیستی، دانشگاه آزاد اسلامی، واحد تهران شمال، تهران، ایران
3 - گروه زیست شناسی، دانشگاه آزاد اسلامی، تنکابن، ایران
4 - گروه ژنتیک، دانشکده علوم و فناوری‌های پیشرفته، دانشگاه آزاد اسلامی، واحد علوم پزشکی تهران، تهران، ایران
5 - گروه میکروب شناسی، دانشکده علوم زیستی، دانشگاه آزاد اسلامی، واحد تهران شمال، تهران، ایران

تاریخ دریافت : 1401/09/08 تاریخ پذیرش : 1402/02/16 تاریخ انتشار : 1402/03/15

کلید واژه: اشریشیا کلی, ESBL, عفونت دستگاه ادراری, سیستمCRISPR/Cas,

چکیده مقاله :

سابقه و هدف: سیستم CRISPR (تکرارهای پالیندرومیک کوتاه فاصله دار منظم خوشه ای) و پروتین‌ های Cas، بخشی از سیستم ایمنی میکروارگانیسم‌ ها می‌ باشد. ژن‌های cas می‌ توانند در کاهش مقاومت آنتی‌ بیوتیکی باکتری‌ ها مشارکت کنند. هدف از این مطالعه ارزیابی فراوانی ژن‌ های cas سیستم CRISPR/Cas در سویه‌ های اشریشیا کلی تولید کننده آنزیم‌ های بتالاکتاماز وسیع الطیف (ESBLs)، جدا شده از بیماران مبتلا به عفونت‌ های دستگاه ادراری می‌ باشد. مواد و روش‌ ها: در این مطالعه مقطعی، 437 نمونه کشت ادرار، از بیمارستان‌ های چالوس جمع آوری شد. جداسازی سویه‌ های اشریشیا کلی، براساس تست‌ های بیوشیمیایی استاندارد و کیت تشخیص تجاری انتروباکتریاسه‌ آ و همچنین حساسیت آنتی‌ بیوتیکی با استفاده از روش انتشار دیسک (کربی بائر) انجام شدند. آزمون دیسک ترکیبی(CDT) نیز برای جدایه‌ هایی که در آزمون قبلی حداقل در برابر یکی از سفالوسپورین‌ های نسل سوم مقاوم بودند، انجام شد. شناسایی مولکولی ژن‌ های cas1، cas2،cas3،cas7 و cas5 با استفاده از روش واکنش زنجیره ای پلی‌ مراز انجام شد. یافته ها: از میان 437 نمونه کشت ادرار 106 نمونه (24/3 درصد) مبتلا به عفونت اشریشیا کلی بودند. بیشترین مقاومت آنتی‌ بیوتیکی مرتبط با آمپی‌سیلین (99 درصد) بود. در میان جدایه‌ های مقاوم، 30 جدایه (88/3 درصد) تولید کننده ESBL بودند. ژنcas1 بیشترین فراوانی (96/2 درصد) را داشت و دیگر ژن‌ های cas تقریباً فراوانی یکسانی داشتند. نتیجه‌ گیری: نتایج مطالعه حاضر نشان داد که درصد قابل توجهی از جدایه‌ های اشریشیا کلی دارای فنوتیپ ESBL بودند که می‌ تواند دلیل بر حضور ژن‌ های بتالاکتاماز وسیع‌ الطیف در این نمونه‌ ها باشد. همچنین، نشان داده شد که رابطه‌ ای بین حضور فنوتیپESBL و توزیع ژن‌ های cas وجود ندارد.

چکیده انگلیسی:

Background & Objectives: CRISPR  system (clustered regularly interspaced short palindromic repeats) and Cas portions is a part of the immune system in microorganisms. The cas genes could be involved in reducing antibiotic resistance in bacteria. The aim of the study was to investigate the frequency of cas genes of the CRISPR/Cas system in Extended Spectrum        Beta-Lactamase (ESBL) producing Escherichia coli isolated from urine culture of patients with urinary tract infection. Materials & Methods: In this cross-sectional study, 437 positive urine culture samples were collected from Chalus hospitals. Escherichia coli strains were isolated based on standard biochemical tests and Enterobacteriaceae commercial diagnostic kit, as well as antibiotic sensitivity using disc diffusion method (Kerby Baer). Combined disk test was conducted for isolates that were resistant to at least one of the third-generation cephalosporins in the foregoing antibiotic susceptibility test. Molecular identification of cas1,cas2,cas3,cas7 and cas5 genes was performed using the PCR method. Results: Out of 437 urin culture samples, 106 samples (24.3%) had E.coli infection. The highest antibiotic resistance was associated with ampicillin (99%). Among the resistant isolates, thirty isolates (88.3%) were ESBL producing. cas1 gene had the highest frequency (96.2%) and other cas genes had almost the same frequency. Conclusion: The results of the present study showed that a significant percentage of E. coli isolates had ESBL phenotype, which may be due to the presence of broad-spectrum beta-lactamase genes in these samples. Besides,  it was shown that there is no relationship between the presence of ESBL phenotype and the distribution of cas genes.    

منابع و مأخذ:


  1. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of bacteriology. 1987;169(12):5429-33.
    2.
  2. Louwen R, Staals RH, Endtz HP, van Baarlen P, van der Oost J. The role of CRISPR-Cas systems in virulence of pathogenic bacteria. Microbiology and Molecular Biology Reviews. 2014;78(1):74-88.
    3.
  3. Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, et al. Evolution and classification of the CRISPR-Cas systems. Nature reviews Microbiology. 2011;9(6):467-77.
    4.
  4. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, et al. An updated evolutionary classification of CRISPR–Cas systems. Nature Reviews Microbiology. 2015;13(11):722-36.
    5.
  5. Sternberg SH, Richter H, Charpentier E, Qimron U. Adaptation in CRISPR-Cas systems. Molecular cell. 2016;61(6):797-808.
    6.
  6. Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: biology, mechanisms and applications. Biochimie. 2015;117:119-28.
    7.
  7. Goren M, Yosef I, Qimron U. Sensitizing pathogens to antibiotics using the CRISPR-Cas system. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2017;30:1-6.
    8.
  8. Gholizadeh P, Aghazadeh M, Asgharzadeh M, Kafil HS. Suppressing the CRISPR/Cas adaptive immune system in bacterial infections. 2017;36(11):2043-51.
    9.
  9. Tao S, Chen H, Li N, & Liang. The Application of the CRISPR-Cas System in Antibiotic Resistance. Infection and Drug Resistance. 2022, 15: 4155.‏
    10.
  10. Mohr KI. History of antibiotics research. How to Overcome the Antibiotic Crisis. 2016:237-72.
    11.
  11. Galindo-Méndez M. Antimicrobial Resistance in Escherichia coli. E. coli Infection: IntechOpen; 2020.
    12.
  12. Lynch JP, 3rd, Clark NM, Zhanel GG. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases). Expert Opin Pharmacother. 2013;14(2):199-210.
    13.
  13. Yang JH, Han SJ, Yoon EK, Lee WS. Evidence of an auxin signal pathway, microRNA167-ARF8-GH3, and its response to exogenous auxin in cultured rice cells. Nucleic acids research. 2006;34(6):1892-9.
    14.
  14. Philippon A, Labia R, Jacoby G. Extended-spectrum beta-lactamases. Antimicrobial agents and chemotherapy. 1989;33(8):1131.
    15.
  15. Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Frontiers in microbiology. 2017;8:1566.
    16.
  16. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute. 2021.
    17.
  17. Livermore DM, Brown DF. Detection of β-lactamase-mediated resistance. Journal of antimicrobial Chemotherapy. 2001;48(suppl_1):59-64.
    18.
  18. Davari K, Nowroozi J, Hosseini F, Akhavan Sepahy A, Mirzaie S. Inhibitor discovery against beta lactamase CTX-M-9 from E. coli by molecular docking, MM/PBSA and molecular dynamics studies. Journal of Cellular and Molecular Research (Iranian Journal of Biology). 2019;32(1):33-46.
    19.
  19. Lesani SS, Soleimani M, Shakib P, Zolfaghari MR. Prevalence of bla CTX-M, bla SHV, and bla TEM Genes in Escherichia coli Strains Isolated From Urinary Tract Infection Samples of Patients in the Intensive Care Unit in Qom, Iran. Gene, Cell and Tissue. 2020;7(2).
    20.
  20. Khaledi A, Esmaeili D, Barzegar KEF, Ghamari N, Razipour H, Rostami H. Prevalence of extended-spectrum-β-lactamase-producing Escherichia coli isolates among uropathogensin a pediatrics hospital. Der Pharma Chemica. 2016;8(3):161-5.
    21.
  21. Rezaie Kahkhaie K, Rezaie Kehkhaie A, Rezaie Kahkhaie L, Koochakzai M, Rezaie Keikhaie K, Nakhaee Moghaddam M. Isolation of Beta-Lactamase Producing Genes (shv, ctx-M1, ctx-M2, ctx-M3) in Escherichia Coli Isolated from Pregnant Woman Patients. World Journal of Peri and Neonatology. 2018;1(1):21-9.
    22.
  22. Masoomi Jahandizi R, Aletaha M, Moosavi M. Evaluation of the Frequency of TEM beta-lactamase gene in patients with urinary tract infections in Bonab County. Cellular and Molecular Researches (Iranian Journal of Biology). 2019;32(3):438-48.
    23.
  23. Hemmati TB, Mehdipour Moghaddam MJ, Salehi Z, Habibzadeh SM. Prevalence of CTX-M-Type β-lactamases in multi-drug resistant Escherichia coli isolates from north of Iran, Rasht. Biological Journal of Microorganism. 2015;3(12).
    24.
  24. Mohajeri P, Darfarin G, Farahani A. Genotyping of ESBL producing Uropathogenic Escherichia coli in west of Iran. International journal of microbiology. 2014;2014.
    25.
  25. Shams F, Hasani A, Pormohammad A, Rezaee MA, Reza M, Nahaie AH, et al. qnrA implicated quinolone resistance in Escherichia coli and Klebsiella pneumoniae clinical isolates from a University Teaching Hospital. Life Sci J. 2014;11(12s):1032-5.
    26.
  26. Khoshvaght H, Haghi F, Zeighami H. Extended spectrum betalactamase producing Enteroaggregative Escherichia coli from young children in Iran. Gastroenterology and Hepatology from bed to bench. 2014;7(2):131.
    27.
  27. Shayan S, Bokaeian M, Shahraki S. Prevalence and molecular characterization of AmpC-producing clinical isolates of Escherichia coli from southeastern Iran. Microbial Drug Resistance. 2014;20(2):104-7.
    28.
  28. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy. 2001;21(5):583-92.
    29.
  29. Chaudhary U, Aggarwal R. Extended spectrum -lactamases (ESBL) - an emerging threat to clinical therapeutics. Indian journal of medical microbiology. 2004;22(2):75-80.
    30.
  30. Alizade H. Escherichia coli in Iran: An Overview of Antibiotic Resistance: A Review Article. Iran J Public Health. 2018;47(1):1-12.
    31.
  31. Haghighatpanah M, Nejad ASM, Mojtahedi A, Amirmozafari N, Zeighami H. Detection of extended-spectrum β-lactamase (ESBL) and plasmid-borne blaCTX-M and blaTEM genes among clinical strains of Escherichia coli isolated from patients in the north of Iran. Journal of global antimicrobial resistance. 2016;7:110-3.
    32.
  32. Yousefipour M, Rasoulinejad M, Hadadi A, Esmailpour N, Abdollahi A, Jafari S, et al. Bacteria producing extended spectrum β-lactamases (ESBLs) in hospitalized patients: Prevalence, antimicrobial resistance pattern and its main determinants. Iranian journal of pathology. 2019;14(1):61.
    33.
  33. Díez-Villaseñor C, Almendros C, García-Martínez J, Mojica FJ. Diversity of CRISPR loci in Escherichia coli. Microbiology (Reading, England). 2010;156(5):1351-61.
    34.
  34. Touchon M, Rocha EP. The small, slow and specialized CRISPR and anti-CRISPR of Escherichia and Salmonella. PloS one. 2010;5(6):e11126.
    35.
  35. Wang G, Song G, Xu Y. Association of CRISPR/Cas system with the drug resistance in Klebsiella pneumoniae. Infection and Drug Resistance. 2020;13:1929.
    36.
  36. Touchon M, Charpentier S, Pognard D, Picard B, Arlet G, Rocha EP, et al. Antibiotic resistance plasmids spread among natural isolates of Escherichia coli in spite of CRISPR elements. Microbiology (Reading, England). 2012;158(12):2997-3004.
    37.
  37. Burley KM, Sedgley CM. CRISPR-Cas, a prokaryotic adaptive immune system, in endodontic, oral, and multidrug-resistant hospital-acquired Enterococcus faecalis. Journal of endodontics. 2012;38(11):1511-5.
    38.
  38. Palmer KL, Gilmore MS. Multidrug-resistant enterococci lack CRISPR-cas. mBio. 2010;1(4).
    39.
  39. Touchon M, Charpentier S, Pognard D, Picard B, Arlet G, Rocha EP, et al. Antibiotic resistance plasmids spread among natural isolates of Escherichia coli in spite of CRISPR elements. Microbiology (Reading). 2012;158(Pt 12):2997-3004.
    40.
  40. Pawluk A, Staals RH. Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species. 2016;1(8):16085.
    41.
_||_

  1. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of bacteriology. 1987;169(12):5429-33.
    2.
  2. Louwen R, Staals RH, Endtz HP, van Baarlen P, van der Oost J. The role of CRISPR-Cas systems in virulence of pathogenic bacteria. Microbiology and Molecular Biology Reviews. 2014;78(1):74-88.
    3.
  3. Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, et al. Evolution and classification of the CRISPR-Cas systems. Nature reviews Microbiology. 2011;9(6):467-77.
    4.
  4. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, et al. An updated evolutionary classification of CRISPR–Cas systems. Nature Reviews Microbiology. 2015;13(11):722-36.
    5.
  5. Sternberg SH, Richter H, Charpentier E, Qimron U. Adaptation in CRISPR-Cas systems. Molecular cell. 2016;61(6):797-808.
    6.
  6. Rath D, Amlinger L, Rath A, Lundgren M. The CRISPR-Cas immune system: biology, mechanisms and applications. Biochimie. 2015;117:119-28.
    7.
  7. Goren M, Yosef I, Qimron U. Sensitizing pathogens to antibiotics using the CRISPR-Cas system. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2017;30:1-6.
    8.
  8. Gholizadeh P, Aghazadeh M, Asgharzadeh M, Kafil HS. Suppressing the CRISPR/Cas adaptive immune system in bacterial infections. 2017;36(11):2043-51.
    9.
  9. Tao S, Chen H, Li N, & Liang. The Application of the CRISPR-Cas System in Antibiotic Resistance. Infection and Drug Resistance. 2022, 15: 4155.‏
    10.
  10. Mohr KI. History of antibiotics research. How to Overcome the Antibiotic Crisis. 2016:237-72.
    11.
  11. Galindo-Méndez M. Antimicrobial Resistance in Escherichia coli. E. coli Infection: IntechOpen; 2020.
    12.
  12. Lynch JP, 3rd, Clark NM, Zhanel GG. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases). Expert Opin Pharmacother. 2013;14(2):199-210.
    13.
  13. Yang JH, Han SJ, Yoon EK, Lee WS. Evidence of an auxin signal pathway, microRNA167-ARF8-GH3, and its response to exogenous auxin in cultured rice cells. Nucleic acids research. 2006;34(6):1892-9.
    14.
  14. Philippon A, Labia R, Jacoby G. Extended-spectrum beta-lactamases. Antimicrobial agents and chemotherapy. 1989;33(8):1131.
    15.
  15. Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Frontiers in microbiology. 2017;8:1566.
    16.
  16. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute. 2021.
    17.
  17. Livermore DM, Brown DF. Detection of β-lactamase-mediated resistance. Journal of antimicrobial Chemotherapy. 2001;48(suppl_1):59-64.
    18.
  18. Davari K, Nowroozi J, Hosseini F, Akhavan Sepahy A, Mirzaie S. Inhibitor discovery against beta lactamase CTX-M-9 from E. coli by molecular docking, MM/PBSA and molecular dynamics studies. Journal of Cellular and Molecular Research (Iranian Journal of Biology). 2019;32(1):33-46.
    19.
  19. Lesani SS, Soleimani M, Shakib P, Zolfaghari MR. Prevalence of bla CTX-M, bla SHV, and bla TEM Genes in Escherichia coli Strains Isolated From Urinary Tract Infection Samples of Patients in the Intensive Care Unit in Qom, Iran. Gene, Cell and Tissue. 2020;7(2).
    20.
  20. Khaledi A, Esmaeili D, Barzegar KEF, Ghamari N, Razipour H, Rostami H. Prevalence of extended-spectrum-β-lactamase-producing Escherichia coli isolates among uropathogensin a pediatrics hospital. Der Pharma Chemica. 2016;8(3):161-5.
    21.
  21. Rezaie Kahkhaie K, Rezaie Kehkhaie A, Rezaie Kahkhaie L, Koochakzai M, Rezaie Keikhaie K, Nakhaee Moghaddam M. Isolation of Beta-Lactamase Producing Genes (shv, ctx-M1, ctx-M2, ctx-M3) in Escherichia Coli Isolated from Pregnant Woman Patients. World Journal of Peri and Neonatology. 2018;1(1):21-9.
    22.
  22. Masoomi Jahandizi R, Aletaha M, Moosavi M. Evaluation of the Frequency of TEM beta-lactamase gene in patients with urinary tract infections in Bonab County. Cellular and Molecular Researches (Iranian Journal of Biology). 2019;32(3):438-48.
    23.
  23. Hemmati TB, Mehdipour Moghaddam MJ, Salehi Z, Habibzadeh SM. Prevalence of CTX-M-Type β-lactamases in multi-drug resistant Escherichia coli isolates from north of Iran, Rasht. Biological Journal of Microorganism. 2015;3(12).
    24.
  24. Mohajeri P, Darfarin G, Farahani A. Genotyping of ESBL producing Uropathogenic Escherichia coli in west of Iran. International journal of microbiology. 2014;2014.
    25.
  25. Shams F, Hasani A, Pormohammad A, Rezaee MA, Reza M, Nahaie AH, et al. qnrA implicated quinolone resistance in Escherichia coli and Klebsiella pneumoniae clinical isolates from a University Teaching Hospital. Life Sci J. 2014;11(12s):1032-5.
    26.
  26. Khoshvaght H, Haghi F, Zeighami H. Extended spectrum betalactamase producing Enteroaggregative Escherichia coli from young children in Iran. Gastroenterology and Hepatology from bed to bench. 2014;7(2):131.
    27.
  27. Shayan S, Bokaeian M, Shahraki S. Prevalence and molecular characterization of AmpC-producing clinical isolates of Escherichia coli from southeastern Iran. Microbial Drug Resistance. 2014;20(2):104-7.
    28.
  28. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy. 2001;21(5):583-92.
    29.
  29. Chaudhary U, Aggarwal R. Extended spectrum -lactamases (ESBL) - an emerging threat to clinical therapeutics. Indian journal of medical microbiology. 2004;22(2):75-80.
    30.
  30. Alizade H. Escherichia coli in Iran: An Overview of Antibiotic Resistance: A Review Article. Iran J Public Health. 2018;47(1):1-12.
    31.
  31. Haghighatpanah M, Nejad ASM, Mojtahedi A, Amirmozafari N, Zeighami H. Detection of extended-spectrum β-lactamase (ESBL) and plasmid-borne blaCTX-M and blaTEM genes among clinical strains of Escherichia coli isolated from patients in the north of Iran. Journal of global antimicrobial resistance. 2016;7:110-3.
    32.
  32. Yousefipour M, Rasoulinejad M, Hadadi A, Esmailpour N, Abdollahi A, Jafari S, et al. Bacteria producing extended spectrum β-lactamases (ESBLs) in hospitalized patients: Prevalence, antimicrobial resistance pattern and its main determinants. Iranian journal of pathology. 2019;14(1):61.
    33.
  33. Díez-Villaseñor C, Almendros C, García-Martínez J, Mojica FJ. Diversity of CRISPR loci in Escherichia coli. Microbiology (Reading, England). 2010;156(5):1351-61.
    34.
  34. Touchon M, Rocha EP. The small, slow and specialized CRISPR and anti-CRISPR of Escherichia and Salmonella. PloS one. 2010;5(6):e11126.
    35.
  35. Wang G, Song G, Xu Y. Association of CRISPR/Cas system with the drug resistance in Klebsiella pneumoniae. Infection and Drug Resistance. 2020;13:1929.
    36.
  36. Touchon M, Charpentier S, Pognard D, Picard B, Arlet G, Rocha EP, et al. Antibiotic resistance plasmids spread among natural isolates of Escherichia coli in spite of CRISPR elements. Microbiology (Reading, England). 2012;158(12):2997-3004.
    37.
  37. Burley KM, Sedgley CM. CRISPR-Cas, a prokaryotic adaptive immune system, in endodontic, oral, and multidrug-resistant hospital-acquired Enterococcus faecalis. Journal of endodontics. 2012;38(11):1511-5.
    38.
  38. Palmer KL, Gilmore MS. Multidrug-resistant enterococci lack CRISPR-cas. mBio. 2010;1(4).
    39.
  39. Touchon M, Charpentier S, Pognard D, Picard B, Arlet G, Rocha EP, et al. Antibiotic resistance plasmids spread among natural isolates of Escherichia coli in spite of CRISPR elements. Microbiology (Reading). 2012;158(Pt 12):2997-3004.
    40.
  40. Pawluk A, Staals RH. Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species. 2016;1(8):16085.
    41.

مقالات مرتبط

حقوق این وب‌سایت متعلق به سامانه مدیریت نشریات دانشگاه آزاد اسلامی است.
حق نشر © 1403-1400

صفحه اصلی| عضویت/ ورود| درباره سند| تماس با ما|
[English] [العربية] [en] [ar]